A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 461-468

  Nelson, Richard E ^a,b   Stenehjem, David ^c,d   Akerley, Wallace ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Cost utility analysis; Epidermal growth factor receptor inhibitor; Markov model; Non small cell lung cancer; Second line treatment; VeriStrat

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STOMATITIS; SURVIVAL RATE; VERISTRAT TEST;

COST-UTILITY ANALYSIS; EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR; MARKOV MODEL; NON-SMALL CELL LUNG CANCER; SECOND-LINE TREATMENT; VERISTRAT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DECISION MAKING, COMPUTER-ASSISTED; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; PROGNOSIS; PROTEOMICS; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; STANDARD OF CARE; SURVIVAL ANALYSIS;

EID: 84887610333     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.021     Document Type: Article

References (29)

1. Cancer prevalence and cost of care projections 2011, National Cancer Institute, [accessed 20.12.11].
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.
3. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September (10)):947-957.
4. Cufer T., Vrdoljak E., Gaafar R., Erensoy I., Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006, 17(April (4)):401-409.
5. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26(September (26)):4244-4252.
6. Akerley W., Boucher K., Rich N., Egbert L., Harker G., Bylund J., et al. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer 2013, 79(March (3)):307-311.
7. Lazzari C., Novello S., Barni S., Aieta M., De Marinis F., De Pas T., et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol 2013, 31(Suppl.). LBA 8005.
8. Gridelli C., Ardizzoni A., Ciardiello F., Hanna N., Heymach J.V., Perrone F., et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(April (4)):430-440.
9. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22(May (9)):1589-1597.
10. Blagden S.P., Charman S.C., Sharples L.D., Magee L.R., Gilligan D. Performance status score: do patients and their oncologists agree?. Br J Cancer 2003, 89(September (6)):1022-1027.
11. Carbone D.P., Salmon J.S., Billheimer D., Chen H., Sandler A., Roder H., et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010, 69(September (3)):337-340.
12. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18(May (10)):2095-2103.
13. Handorf E.A., McElligott S., Vachani A., Langer C.J., Bristol Demeter M., Armstrong K., et al. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract/Am Soc Clin Oncol 2012, 8(September (5)):267-274.
14. Medicare Part B drug average sales price 2013, http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html [accessed 05.08.13].
15. Carlson J.J., Reyes C., Oestreicher N., Lubeck D., Ramsey S.D., Veenstra D.L. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008, 61(September (3)):405-415.
16. Kutikova L., Bowman L., Chang S., Long S.R., Obasaju C., Crown W.H. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005, 50(November (2)):143-154.
17. Ray T. Phase III Data Shows Biodesix's VeriStrat Proteomic Can Predict Response to Tarceva. Pharmacogenomics Reporter 2010.
18. Nafees B., Stafford M., Gavriel S., Bhalla S., Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008, 6:84.
19. Ossa D.F., Briggs A., McIntosh E., Cowell W., Littlewood T., Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 2007, 25(3):223-237.
20. Carlson J.J., Garrison L.P., Ramsey S.D., Veenstra D.L. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009, 12(January-February (1)):20-27.
21. Fenwick E., Marshall D.A., Levy A.R., Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006, 6:52.
22. Grosse S.D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008, 8(April (2)):165-178.
23. Braithwaite R.S., Meltzer D.O., King J.T., Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 2008, 46(April (4)):349-356.
24. Greenberg D., Earle C., Fang C.H., Eldar-Lissai A., Neumann P.J. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010, 102(January (2)):82-88.
25. Ness R.M., Holmes A.M., Klein R., Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000, 95(July (7)):1800-1811.
26. Hunt T.L., Luce B.R., Page M.J., Pokrzywinski R. Willingness to pay for cancer prevention. Pharmacoeconomics 2009, 27(4):299-312.
27. Leighl N.B., Shepherd F.A., Kwong R., Burkes R.L., Feld R., Goodwin P.J. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002, 20(March (5)):1344-1352.
28. Holmes J., Dunlop D., Hemmett L., Sharplin P., Bose U. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004, 22(9):581-589.
29. Vergnenegre A., Corre R., Berard H., Paillotin D., Dujon C., Robinet G., et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol 2011, 6(January (1)):161-168.